DFJ:NYE-WisdomTree Japan SmallCap Dividend Fund (USD)

ETF | Japan Stock |

Last Closing

USD 80.66

Change

+0.52 (+0.65)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Japan Stock

Symbol Name Price(Change) Market Cap
FLJP Franklin FTSE Japan ETF

+0.18 (+0.60%)

USD 2.18B
DBJP Xtrackers MSCI Japan Hedged Eq..

+1.14 (+1.62%)

USD 0.44B
FLJH Franklin FTSE Japan Hedged ETF

+0.50 (+1.67%)

USD 0.08B
DXJ WisdomTree Japan Hedged Equity..

+2.05 (+1.97%)

N/A
EWJ iShares MSCI Japan ETF

+0.46 (+0.65%)

N/A
GSJY Goldman Sachs ActiveBeta® Jap..

+0.35 (+0.90%)

N/A
HEWJ iShares Currency Hedged MSCI J..

+0.68 (+1.68%)

N/A
JPXN iShares JPX-Nikkei 400 ETF

+0.61 (+0.80%)

N/A
SCJ iShares MSCI Japan Small-Cap E..

+0.61 (+0.78%)

N/A

ETFs Containing DFJ

N/A

Market Performance

  Market Performance vs. Industry/Classification (Japan Stock) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.69% 5% F 49% F
Dividend Return 1.18% 65% D 23% F
Total Return 8.87% 5% F 43% F
Trailing 12 Months  
Capital Gain 17.90% 35% F 51% F
Dividend Return 2.13% 5% F 30% F
Total Return 20.03% 35% F 48% F
Trailing 5 Years  
Capital Gain 18.57% 15% F 55% F
Dividend Return 12.50% 55% F 45% F
Total Return 31.07% 15% F 51% F
Average Annual (5 Year Horizon)  
Capital Gain 3.89% N/A N/A 52% F
Dividend Return 6.47% N/A N/A 52% F
Total Return 2.58% N/A N/A 55% F
Risk Return Profile  
Volatility (Standard Deviation) 15.28% N/A N/A 63% D
Risk Adjusted Return 42.36% N/A N/A 59% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike